Memsel Inc.

Memsel Inc., a self-certified small disadvantaged business based in Fort Worth, Texas, develops hydrogel-based drug delivery systems and biomedical technologies for federal medical research programs as a prime contractor operating exclusively under small-business set-asides. The company competes as a 100% prime-award vendor with no recorded subcontract footprint, focusing on SBIR and STTR Phase I contracts and military medical research grants funded by the Defense Health Agency, the National Institutes of Health, and the Army Medical Command.

Memsel's recent award portfolio spans four federal transactions totaling $1.1 million in combined potential value, though $5.6 million has been obligated across the set, representing advanced-stage performance or grant drawdown. The Defense Health Agency anchors two awards ($250 thousand combined potential value) — a $249.7 thousand SBIR Phase I purchase order for an advanced hydrogel-based drug delivery system for traumatic brain injury neuroprotection (awarded October 2024, completing May 2025) and a $4.52 million military medical research and development project grant (awarded September 2025, completing August 2027) supporting advanced wound care solutions for multi-drug-resistant infections and hemorrhage control in battlefield conditions. The National Institutes of Health awarded a $593.8 thousand definitive contract under SBIR Topic 5 for precision brain targeting and non-invasive drug delivery (awarded February 2026, completing March 2027). The Army Medical Command funded a $249.9 thousand STTR Phase I purchase order for a bacteriophage-encapsulated hydrogel addressing drug-resistant bacterial infections (awarded March 2022, completed October 2022).

The three customer agencies account for 100% of awards, with NIH and MEDCOM holding slight edges in potential value. Two awards totaling $594 thousand reach completion within the next twenty-four months, creating near-term recompete exposure. Memsel's capability portfolio centers on hydrogel formulation, controlled drug delivery, bacteriophage encapsulation, and biomedical wound care technologies applied to military medical and traumatic injury applications — positioning the company as a specialized life sciences and biomedical engineering vendor competing primarily through federal small-business SBIR and STTR mechanisms rather than larger IDIQs or GWACs.

Memsel, a leader in biotechnology R&D, specializes in health and infection therapeutics through advanced phage therapies and targeted delivery systems. We address critical challenges in trauma care and wound infection management. Our innovations include a multicomponent hydrogel for bleeding control, tissue healing, and infection prevention, and phage-based technology targeting drug-resistant pathogens. Our solutions advance trauma care and infection control, targeting both military and civilian applications.